Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene

Molecular Oncology

Volumn 2, Issue 4, 2008, Pages 296-316

  Bartkova, Jirina ^a   Tommiska, Johanna ^b   Oplustilova, Lenka ^a,c   Aaltonen, Kirsimari ^b   Tamminen, Anitta ^b   Heikkinen, Tuomas ^b   Mistrik, Martin ^a,c   Aittomäki, Kristiina ^b   Blomqvist, Carl ^b,d   Heikkilä, Päivi ^b   Lukas, Jiri ^a   Nevanlinna, Heli ^b   Bartek, Jiri ^a,c  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BRCA1 BRCA2; Breast cancer; DNA damage response; ER PR ERBB2 triple negative tumours; Familial cancer predisposition; MRE11 RAD50 NBS1 complex; p53; Tumour suppressors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2AX; MRE11 PROTEIN; NIBRIN; PROTEIN P53; RAD50 PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENE TRANSFER; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MRE11 GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL; TUMOR GENE; WILD TYPE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTANT PROTEINS; NUCLEAR PROTEINS; PEDIGREE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 56649086648     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.09.007     Document Type: Article

References (84)

1. Aagaard L., Lukas J., Bartkova J., Kjerulff A.A., Strauss M., and Bartek J. Aberrations of p16Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int. J. Cancer 61 (1995) 115-120
2. Adams K.E., Medhurst A.L., Dart D.A., and Lakin N.D. Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex. Oncogene 25 (2006) 3894-3904
3. Ahmed M., and Rahman N. ATM and breast cancer susceptibility. Oncogene 25 (2006) 5906-5911
4. Angele S., Treilleux I., Bremond A., Taniere P., and Hall J. Altered expression of DNA double-strand break detection and repair proteins in breast carcinomas. Histopathology 43 (2003) 347-353
5. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C.M., Gannon J.V., and Lane D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6 (1991) 1699-1703
6. Bartek J., and Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr. Opin. Cell Biol. 19 (2007) 238-245
7. Bartek J., Bartkova J., and Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26 (2007) 7773-7779
8. Bartek J., Lukas C., and Lukas J. Checking on DNA damage in S phase. Nature Rev. Mol. Cell. Biol. 5 (2004) 792-804
9. Bartkova J., Horejsi Z., Koed K., Guldberg P., Krämer A., Sehested M., Nesland J., Lukas C., Ørntoft T., Lukas J., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
10. Bartkova J., Bakkenist C.J., Rajpert-De Meyts E., Skakkebaek N.E., Sehested M., Lukas J., Kastan M.B., and Bartek J. ATM activation in normal human tissues and testicular cancer. Cell Cycle 4 (2005) 838-845
11. Bartkova J., Horejsi Z., Sehested M., Nesland J.M., Rajpert-De M.E., Skakkebaek N.E., Stucki M., Jackson S.P., Lukas J., and Bartek J. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26 (2007) 7414-7422
12. Bekker-Jensen S., Lukas C., Melander F., Bartek J., and Lukas J. Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are coordinated by Mdc1/NFBD1. J. Cell Biol. 170 (2005) 201-211
13. Bekker-Jensen S., Lukas C., Kitagawa R., Melander F., Kastan M.B., Bartek J., and Lukas J. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 173 (2006) 195-206
14. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtain N., and Hellday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
15. 2/M checkpoint. EMBO J 22 (2003) 6610-6620
16. Celis J.E., Gromova I., Cabezón T., Gromov P., Shen P., Timmermans-Wielenga V., Rank F., and Moreira J.M.A. Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: Relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Molecular Oncology 1 (2007) 321-349
17. Cerosaletti K., Wright J., and Concannon P. Active role for nibrin in the kinetics of atm activation. Mol. Cell. Biol. 26 (2006) 1691-1699
18. Cimprich K.A., and Cortez D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9 (2008) 616-617
19. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
20. Cox A., Dunning A.M., Garcia-Closas M., Balasubramanian S., Reed M.W., Pooley K.A., Scollen S., Baynes C., Ponder B.A., Chanock S., et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39 (2007) 352-358
21. Di Micco R., Fumagalli M., Cicalese A., Piccini S., Gasparini P., Luise C., Shurra C., Garre M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 (2006) 638-642
22. DiTullio R.A., Mochan T.A., Venere M., Bartkova J., Sehested M., Bartek J., and Halazonetis T.D. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nature Cell Biol. 4 (2002) 998-1002
23. Ebi H., Matsuo K., Sugito N., Suzuki M., Osada H., Tajima K., Ueda R., and Takahashi T. Novel NBS1 heterozygous germ line mutation causing MRE11-binding domain loss predisposes to common types of cancer. Cancer Res. 67 (2007) 11158-11165
24. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 7 (2005) 93-100
25. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 7 (2005) 465-469
26. Eerola H., Heinonen M., Heikkila P., Kilpivaara O., Tamminen A., Aittomaki K., Blomqvist C., Ristimäki A., and Nevanlinna H. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 10 (2008) R17
27. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
28. Erkko H., Xia B., Nikkilä J., Schleutker J., Syrjäkoski K., Mannermaa A., Kallioniemi A., Pylkäs K., Karppinen S.M., Rapakko K., et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446 (2007) 316-319
29. Fagerholm R. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. In: Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjäkoski K., Kallioniemi A., Kilpivaara O., Mannermaa A., and Kosma V.M. (Eds). Nat. Genet 40 (2008) 8444-8845
30. Falck J., Petrini J.H.J., Williams B.R., Lukas J., and Bartek J. The DNA damage-dependent intra-S-phase checkpoint is regulated by parallel pathways. Nat. Genet. 30 (2002) 290-294
31. Falck J., Coates J., and Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434 (2005) 605-611
32. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
33. Ganguly A. An update on conformation sensitive gel electrophoresis. Hum. Mutat. 19 (2002) 334-342
34. Giannini G., Ristori E., Cerignoli F., Rinaldi C., Zani M., Viel A., Ottini L., Crescenzi M., Martinotti S., Bignami M., et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 3 (2002) 248-254
35. Giannini G., Rinaldi C., Ristori E., Ambrosini M.I., Cerignoli F., Viel A., Bidoli E., Berni S., D'Amati G., Scambia G., et al. Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene 23 (2004) 2640-2647
36. Goldberg M., Stucki M., Falck J., D'Amours D., Rahman D., Pappin D., Bartek J., and Jackson S.P. The MDC1 protein is required for the intra-S-phase DNA damage checkpoint. Nature 421 (2003) 952-956
37. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., DiTullio Jr. R.A., Kastrinakis N.G., Levy B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
38. Górski B., Debniak T., Masojć B., Mierzejewski M., Medrek K., Cybulski C., Jakubowska A., Kurzawski G., Chosia M., Scott R., et al. Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int. J. Cancer 106 (2003) 379-381
39. Halazonetis T., Gorgoulis V., and Bartek J. An oncogene-induced DNA damage model for cancer development. Science 319 (2008) 1352-1355
40. Heikkinen K., Rapakko K., Karppinen S.M., Erkko H., Knuutila S., Lundán T., Mannermaa A., Børresen-Dale A.L., Borg A., Barkardottir R.B., et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27 (2006) 1593-1599
41. Horejsi Z., Falck J., Bakkenist C., Kastan M., Lukas J., and Bartek J. Distinct functional domains of Nbs1 modulate the timing and magnitude of ATM activation after low doses of ionizing radiation. Oncogene 23 (2004) 3122-3127
42. Hsu H.M., Wang H.C., Chen S.T., Hsu G.C., Shen C.Y., and Yu J.C. Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1complex. Cancer Epidemiol Biomarkers Prev. 16 (2007) 2024-2032
43. Jazayeri A., Falck J., Lukas C., Bartek J., Smith G.C.M., Lukas J., and Jackson S.P. ATM- and cell cycle-dependent ATR regulation in response to DNA double-strand breaks. Nat. Cell Biol. 8 (2006) 37-45
44. Krämer A., Mailand N., Lukas C., Syljuåsen R.G., Wilkinson C.J., Nigg E.A., Bartek J., and Lukas J. Centrosome-associated Chk1 prevents premature actibation of cyclin-D-Cdk1 kinase. Nature Cell Biol. 6 (2004) 884-891
45. Kastan M., and Bartek J. Cell cycle checkpoints and cancer. Nature 432 (2004) 316-323
46. Kilpivaara O., Bartkova J., Eerola H., Syrjakoski K., Vahteristo P., Lukas J., Blomqvist C., Holli K., Heikkila P., Sauter G., et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int. J. Cancer 113 (2005) 575-580
47. Lavin M.F. ATM and the Mre11 complex combine to recognize and signal DNA double strand breaks. Oncogene 26 (2007) 7749-7758
48. Lu J., Wei Q., Bondy M.L., Li D., Brewster A., Shete S., Yu T.K., Sahin A., Meric-Bernstam F., Hunt K.K., Singletary S.E., et al. Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women < or =55 years. Carcinogenesis 27 (2006) 2209-2216
49. Lukas C., Bartkova J., Latella L., Falck J., Mailand N., Schroeder T., Sehested M., Lukas J., and Bartek J. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation, yet correlates with tissue biology. Cancer Res. 61 (2001) 4990-4993
50. Lukas C., Falck J., Bartkova J., Bartek J., and Lukas J. Distinct spatio-temporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol. 5 (2003) 255-260
51. Lukas C., Melander F., Stucki M., Falck J., Bekker-Jensen S., Goldberg M., Lerenthal Y., Jackson S.P., Bartek J., and Lukas J. Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AX-dependent chromatin retention. EMBO J. 23 (2004) 2674-2683
52. Lukas J., Lukas C., and Bartek J. Mammalian cell cycle checkpoints: Signalling pathways and their organization in space and time. DNA Repair 3 (2004) 997-1007
53. Nevanlinna H., and Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25 (2006) 5912-5919
54. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V., Gaciong Z., et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7 (2005) 193-204
55. Rupnik A., Grenon M., and Lowndes N. The MRN complex. Curr. Biol. 18 (2008) R455-R457
56. Santoni-Rugiu E., Falck J., Mailand N., Bartek J., and Lukas J. Involvement of Myc activity in a G1/S-promoting mechanism parallel to the pRb/E2F pathway. Mol. Cell. Biol. 20 (2000) 3497-3509
57. Sartori A., Lukas C., Coates J., Mistrik M., Fu S., Bartek J., Baer R., Lukas J., and Jackson S.P. Human CtIP promotes DNA end resection. Nature 450 (2007) 509-514
58. Schultz L.B., Chehab N.H., Malikzay A., and Halazonetis T.D. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151 (2000) 1381-1390
59. Seal S., Thompson D., Renwick A., Elliott A., Kelly P., Barfoot R., Chagtai T., Jayatilake H., Ahmed M., Spanova K., et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38 (2006) 1239-1241
60. Seemanová E., Jarolim P., Seeman P., Varon R., Digweed M., Swift M., and Sperling K. Cancer risk of heterozygotes with the NBN founder mutation. J. Natl. Cancer Inst. 24 (2007) 1875-1880
61. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., and Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128 (2007) 157-170
62. Shiloh Y. The ATM-mediated DNA damage response: taking shape. Trends Biochem. Sci. 31 (2006) 402-410
63. Stewart G.S., Maser R.S., Stankovic T., Bressan D.A., Kaplan M.I., Jaspers N.G.J., Raams A., Byrd P.J., Petrini J.H.J., and Taylor A.M.R. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 99 (1999) 577-587
64. Soderlund K., Stal O., Skoog L., Rutqvist L.E., Nordenskjold B., and Stenmark Askmalm M. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007) 50-58
65. Stracker T.H., Theunissen J.W., Morales M., and Petrini J.H. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair 3 (2004) 845-854
66. Stracker T.H., Morales M., Couto S.S., Hussein H., and Petrini J.H. The carboxy terminus of NBS1 is required for induction of apoptosis by the MRE11 complex. Nature 447 (2007) 218-221
67. Sørensen C.S., Syljuåsen R.G., Falck J., Schroeder T., Rönnstrand L., Zhou B.-B., Bartek J., and Lukas J. Chk1 regulates the S-phase checkpoint by coupling the physiological turnover and ionising radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3 (2003) 247-258
68. Sørensen C.S., Hansen L.T., Dziegielewski J., Syljuåsen R.G., Lundin C., Bartek J., and Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 7 (2005) 195-201
69. Syljuasen R.G., Sorensen C.S., Hansen L.T., Fugger K., Lundin C., Johansson F., Helleday T., Sehested M., Lukas J., and Bartek J. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol. 25 (2005) 3553-3562
70. Syrjäkoski K., Vahteristo P., Eerola H., Tamminen A., Kivinummi K., Sarantaus L., Holli K., Blomqvist C., Kallioniemi O.P., Kainu T., et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J. Natl. Cancer Inst. 92 (2000) 1529-1531
71. Tassan J.P., Schultz S.J., Bartek J., and Nigg A.E. Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). J. Cell Biol. 127 (1994) 467-478
72. Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J., Ristimaki A., von Smitten K., Aittomaki K., Heikkila P., et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11 (2005) 5098-5103
73. Tommiska J., Seal S., Renwick A., Barfoot R., Baskcomb L., Jayatilake H., Bartkova J., Tallila J., Kaare M., Tamminen A., et al. Evaluation of RAD50 in familial breast cancer predisposition. Int. J. Cancer 118 (2006) 2911-2916
74. Tommiska J., Bartkova J., Heinonen M., Hautala L., Kilpivaara O., Eerola H., Aittomäki K., Hofstetter B., Lukas J., Blomqvist C., et al. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 27 (2008) 2501-2506
75. Trenz K., Smith E., Smith S., and Costanzo V. ATM and ATR promote Mre11 dependent restart of collapsed replication forks and prevent accumulation of DNA breaks. EMBO J. 25 (2006) 1764-1774
76. Uziel T., Lerenthal Y., Moyal L., Andegeko Y., Mittelman L., and Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 22 (2003) 5612-5621
77. Vahteristo P., Eerola H., Tamminen A., Blomqvist C., and Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br. J. Cancer 84 (2001) 704-708
78. Vahteristo P., Bartkova J., Eerola H., Syrjakoski K., Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K., Heikkila P., et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71 (2002) 432-438
79. Varon R., Vissinga C., Platzer M., Cerosaletti K.M., Chrzanowska K.H., Saar K., Beckmann G., Seemanova E., Cooper P.R., Nowak N.J., et al. Nibrin, a novel DNA double strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93 (1998) 467-476
80. Vehmanen P., Friedman L., Eerola H., McClure M., Ward B., Sarantaus L., Kainu T., Syrjäkoski K., Pyrhönen S., Kallioniemi O., et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: strong evidence for additional susceptibility genes. Hum. Mol. Genet. 6 (1997) 2309-2315
81. Vojtesek B., Bartek J., Midgley C.A., and Lane D.P. An immunochemical analysis of human p53: New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods 151 (1992) 237-244
82. Walsh T., and King M.C. Ten genes for inherited breast cancer. Cell 11 (2007) 103-105
83. Wen Q., Scorah J., Phear G., Rodgers G., Rodgers S., and Meuth M. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol. Biol. Cell 19 (2008) 1693-1705
84. Zhou B.B., and Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer 4 (2004) 216-225